A Chinese collaborative is working on a similar vaccine to the one developed by the University of Oxford that is now in the hands of AstraZeneca known as AZD1222. Based on a chimpanzee adenovirus—like the “Oxford vaccine—this new preclinical vaccine candidate will now enter the clinical trials process. Jointly developed by China’s Tsinghua University and Tianjin Medical University, Chinese state owned media Health Times reports the group has licensed the technology to a biotech venture called Walvax Biotechnology Co; the firm is now working on the development of a facility to produce early-stage investigational products. Again, according to state-sponsored news, they will have the capacity to produce 200 million doses per annum by mid-2021.
Way Behind AstraZeneca
Of course, the Oxford vaccine (AZD1222) was one of the first promising COVID-19 vaccines out of the research and development stage gate. Now in late-stage Phase 3 clinical trials from the UK to South Africa, Brazil and India, Reuters reports that data from the UK and Brazil found the efficacy at 62% for trial participants given the full two dose regimen. In an interesting twist reported on by TrialSite, the vaccine ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).